TC BioPharm(TCBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TCBP TC BioPharm

Trading 04-19 12:52:01 EDT

1.45

+0.03

+2.18%

High1.49	Low1.38	Vol62.92K
Open1.49	D1 Closing1.42	Amplitude7.75%
Mkt Cap4.64M	Tradable Cap3.36M	Total Shares3.20M
T/O90.42K	T/O Rate2.72%	Tradable Shares2.31M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"TCBP","market":"US","secType":"STK","nameCN":"TC BioPharm","latestPrice":1.451,"timestamp":1713545230733,"preClose":1.42,"halted":0,"volume":62923,"delay":0,"floatShares":2313800,"shares":3195132,"eps":-20.491838,"marketStatus":"Trading","marketStatusCode":2,"change":0.031,"latestTime":"04-19 12:52:01 EDT","open":1.49,"high":1.49,"low":1.38,"amount":90420.06784650001,"amplitude":0.077465,"askPrice":1.46,"askSize":100,"bidPrice":1.43,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-20.491838,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1713556800000},"adr":0,"listingDate":1644555600000,"adjPreClose":1.42,"adrRate":20,"preHourTrading":{"tag":"盘前","latestPrice":1.5,"preClose":1.42,"latestTime":"08:37 EDT","volume":2064,"amount":3111.610032,"timestamp":1713530247162},"postHourTrading":{"tag":"盘后","latestPrice":1.5,"preClose":1.42,"latestTime":"19:56 EDT","volume":2343,"amount":3629.7593,"timestamp":1713484586841},"volumeRatio":0.678569},"requestUrl":"/m/hq/s/TCBP","defaultTab":"news","newsList":[{"id":"2426498207","title":"BSGM, WAVE and TCBP among pre-market losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2426498207","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2426498207?lang=en_us&edition=fundamental","pubTime":"2024-04-10 20:22","pubTimestamp":1712751778,"startTime":"0","endTime":"0","summary":"Losers: PainReform Ltd  -15%. Biosig Technologies  -14%. Palladyne AI Corp.  -11%. Laser Photonics Corp  -10% announce technology partnership to integrate game-changing laser systems into Industry-leading Robotics. Eco Wave Power Global  -10%. DocGo  -10%. BYND Cannasoft Enterprises  -9%.  TC BioPharm  -9%. Hexcel Corp.  -9% it names former Spirit AeroSystems head Gentile as new President/CEO. SoundHound  -8% on $150M equity distribution pact. Antelope Enterprise Holdings Ltd  -8%. ClearOne  -8%. Auddia  -8%. Candel Therapeutics  -7%. Anghami  -7%. Zooz Power Ltd  -6%. Motorsport Games  -6%. Acrivon Therapeutics  -5% presents data at AACR annual meeting highlighting the capabilities of Acrivon Predictive Precision Proteomics.   More on Pre-market losers & stocks.  Eco Wave Power Global AB   Q4 2023 Earnings Call Transcript Eco Wave Power attracts Shell for wave energy feasibility studies for U.S. coastline TC Biopharm shares jump on signing non-binding LOI for two allogeneic CAR-NK the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4088521-bsgm-wave-and-tcbp-among-pre-market-losers","is_publish_highlight":false,"gpt_icon":0},{"id":"2425552192","title":"Altice USA, Genfit, Brooge Energy among premarket losers' pack","url":"https://stock-news.laohu8.com/highlight/detail?id=2425552192","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2425552192?lang=en_us&edition=fundamental","pubTime":"2024-04-05 20:29","pubTimestamp":1712320194,"startTime":"0","endTime":"0","summary":"ARCA biopharma  -7%afterannounces executive and board leadership changes.Altice USA ATUS-5%as Wells Fargo cuts estimates, downgrades amid fiber competition worries.","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4087541-altice-usa-genfit-brooge-energy-among-premarket-losers-pack","is_publish_highlight":false,"gpt_icon":0},{"id":"2425871341","title":"Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2425871341","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2425871341?lang=en_us&edition=fundamental","pubTime":"2024-04-05 02:39","pubTimestamp":1712255989,"startTime":"0","endTime":"0","summary":"U.S. stocks turned lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday.\n\nThe Dow traded down 0.59% to 38,894.58 while the NASDAQ fell 0.10% to 16,261.88. The S&amp;P 500 also fell, dropping, 0.28% to 5,197.03.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/04/38098514/dow-dips-over-200-points-rpm-international-shares-fall-after-q3-results","is_publish_highlight":false,"gpt_icon":0},{"id":"2425577348","title":"TC BioPharm Shares Rise 63% After Letter Intent to Buy Cancer Therapy Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2425577348","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2425577348?lang=en_us&edition=fundamental","pubTime":"2024-04-05 01:12","pubTimestamp":1712250720,"startTime":"0","endTime":"0","summary":"TC BioPharm shares rose after the company said it executed a non-binding letter of intent to buy NK, or natural killer, platform technology to treat both solid tumors and other indications.Shares were up 63% to $2.12 in recent trading. The stock hit its 52-week low of 85 cents on Feb. 5, and is down 94% in the past 12 months.The clinical stage biotechnology company said the target asset acquisition covers the proprietary manufacturing process of two allogeneic CAR-NK therapeutics, both of which TC BioPharm believes are valuable as monotherapies as well as in conjunction with TCB-008 in the future.Under the terms of the letter of intent, TC BioPharm has been granted exclusivity while the parties work in good faith on drafting a definitive agreement.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2425723310","title":"BRNS, UPC and KWE among mid-day movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2425723310","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2425723310?lang=en_us&edition=fundamental","pubTime":"2024-04-05 01:06","pubTimestamp":1712250403,"startTime":"0","endTime":"0","summary":"Gainers: Allurion Technologies  +107%. Candel Therapeutics  +93%. TC BioPharm plc  +62%. HWH International  +47%. Barinthus Biotherapeutics Plc.  +41%. Eiger BioPharmaceuticals  +37%. Macrogenics  +33%. E-Home Household Service Holdings Ltd  +30%. Niu Technologies  +27%.  Sportsman's Warehouse Holdings  +24%.  Losers: eFFECTOR Therapeutics  -81%. AXT  -25%. Achilles Therapeutics Plc  -24%. Keyarch Acquisition Corp  -23%. KWESST Micro Systems  -22%. Lamb Weston Holdings  -19%. XTI Aerospace  -18%. Inotiv  -18%. Universe Pharmaceuticals  -18%. Riley Exploration Permian  -17%.   More on Mid-day movers & stocks.  Seeking Alpha’s Quant Rating on Barinthus Biotherapeutics Historical earnings data for Barinthus Biotherapeutics Financial information for Barinthus Biotherapeutics Seeking Alpha’s Quant Rating on KWESST Micro Systems Historical earnings data for KWESST Micro Systems","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4087355-brns-upc-and-kwe-among-mid-day-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2424390770","title":"ARCA biopharma, Achilles Therapeutics, MSP Recovery among healthcare movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2424390770","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2424390770?lang=en_us&edition=fundamental","pubTime":"2024-04-04 22:00","pubTimestamp":1712239216,"startTime":"0","endTime":"0","summary":"Gainers: TC Biopharm ADR  +144%. Allurion Technologies  +65%. Tevogen Bio Holdings  +64%. Candel Therapeutics  +34%. MacroGenics  +28%.  Losers: eFFECTOR Therapeutics  -81%. Achilles Therapeutics ADR  -24%. Flora Growth  -15%. MSP Recovery  -11%. ARCA biopharma  -9%.   S&P 500 Health Care Sector +0.45% to 1687.02. Health Care Equipment & Services +0.43% to 1950.98. Pharmaceuticals, Biotechnology & Life Science which contributes 58% to index is +0.49% to 1385.84.  More on Health Care Select Sector SPDR  XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Eli Lilly tops S&P 500 healthcare sector in Q1 as weight loss frenzy continues Johnson & Johnson, Boston Scientific least shorted stocks in S&P 500 healthcare sector for Feb-end","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4087277-arca-biopharma-achilles-therapeutics-msp-recovery-among-healthcare-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2424394959","title":"EIGR, ADXN and BROG are among premarket gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2424394959","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2424394959?lang=en_us&edition=fundamental","pubTime":"2024-04-04 21:20","pubTimestamp":1712236844,"startTime":"0","endTime":"0","summary":"Gainers: Tevogen  +95%. TC BioPharm  +61% Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies.  HWH International  +57%. Zhongchao  +27%. Allurion Technologies  +27% Expands Virtual Care Suite to the United States  Candel Therapeutics  +23% stock soars on positive data from mid-stage pancreatic cancer drug trial.  Eiger BioPharmaceuticals  +17%. Addex Therapeutics  +15%. Levi Strauss  +14%. Brooge Energy  +12%.   More on premarket gainers & stock  Addex stock climbs on launch of new company, Neurosterix Eiger reportedly files for Chapter 11, stock plunges 52% Historical earnings data for Addex Therapeutics Financial information for Addex Therapeutics Seeking Alpha’s Quant Rating on Brooge Energy","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4087242-eigr-adxn-and-brog-are-among-premarket-gainers","is_publish_highlight":false,"gpt_icon":0},{"id":"2424949163","title":"TC Biopharm shares jump on signing non-binding LOI for two allogeneic CAR-NK therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2424949163","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2424949163?lang=en_us&edition=fundamental","pubTime":"2024-04-04 21:18","pubTimestamp":1712236738,"startTime":"0","endTime":"0","summary":"TC Biopharm  shares surge 59% premarket on signing a LOI to acquire the proprietary manufacturing process of two allogeneic CAR-NK therapeutics, CD-70 CAR-NK technology and HER2 CAR-NK technology. The proposed transaction aims to expand its therapeutic platform and utilize natural killer cells for solid tumor treatment.  The acquisition aims to enhance the clinical therapeutic potential of TCB-008 and leverage existing expertise to refine manufacturing processes and advance multiple platforms targeting solid tumors. At present, there can be no assurance that a definitive agreement will be executed or that the proposed transaction will be consummated within the terms or timeframe currently contemplated. \"This proposed asset acquisition would leverage our strengths in optimizing manufacturing processes and developing new cell therapies rapidly to the clinical stage, as well as our core asset on asset base expansion and combination efforts with TCB-008. By merging complimentary technologi","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/638647102/image_638647102.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/638647102/image_638647102.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4087239-tc-biopharm-shares-jump-on-signing-non-binding-loi-for-two-allogeneic-car-nk-therapeutics","is_publish_highlight":false,"gpt_icon":0},{"id":"2424963233","title":"TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2424963233","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2424963233?lang=en_us&edition=fundamental","pubTime":"2024-04-04 20:32","pubTimestamp":1712233920,"startTime":"0","endTime":"0","summary":"EDINBURGH, Scotland, April 4, 2024 /PRNewswire/ -- TC BioPharm  PLC   a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a non-binding letter of intent as part of its M&A strategy aimed at expanding its therapeutic platform and leveraging NK  cells in treating both solid tumors and other indications.\"With the difficult times in cell therapy we see this as a unique opportunity to aggressively expand our asset base in other immune cells and immune responder technologies, which we believe will further enhance TCBP as a leader in cell therapy and increase our future value,\" said Mr. Bryan Kobel, CEO of TC BioPharm. \"We believe this proposed asset acquisition brings not just a new and expanded opportunity in cancer, but synergies in combination efforts with TCB-008 in numerous indications. This proposed asset acquisition would leverage our strengths in optimizing manufacturing ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23027393","is_publish_highlight":false,"gpt_icon":0},{"id":"2424022617","title":"BRIEF-TCBP Increasing Treatment Capacity With Expanded Manufacturing Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2424022617","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2424022617?lang=en_us&edition=fundamental","pubTime":"2024-04-03 01:11","pubTimestamp":1712077912,"startTime":"0","endTime":"0","summary":"April 2  - TC BioPharm Ltd   :   * TCBP INCREASING TREATMENT CAPACITY WITH EXPANDED MANUFACTURING PROCESS   * TC BIOPHARM LTD: UNDERTAKING, WHICH WILL UTILIZE ITS CURRENT INFRASTRUCTURE, WILL PROVIDE A COST REDUCTION OF 85% PER PATIENT TREATMENT   * TC BIOPHARM LTD: EXPECTS TO IMPLEMENT IMPROVED MANUFACTURE PROCESS INTO ITS CURRENT FACILITY IN NEXT 24 MONTHS   * TC BIOPHARM: DEVELOPING STREAMLINED,SCALED-UP MANUFACTURING PROCESS TO INCREASE TREATMENTS CAPACITY FROM 52 PATIENT TREATMENTS/YEAR TO MORE THAN 1,000Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2424010518","title":"TCBP to raise treatment capacity with expanded manufacturing process","url":"https://stock-news.laohu8.com/highlight/detail?id=2424010518","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2424010518?lang=en_us&edition=fundamental","pubTime":"2024-04-02 21:05","pubTimestamp":1712063148,"startTime":"0","endTime":"0","summary":"TC BioPharm PLC  announced that it is developinga streamlined and scaled-up manufacturing process which will increase its treatments capacity from 52 patient treatments per year to more than 1,000. This undertaking, which will utilize its current infrastructure, will provide a cost reduction of 85% per patient treatment.The company expects to implement the improved manufacture process into its current facility in the next 24 months. Source: Press Release. More on TC Biopharm  TCBP announces exercise of series D warrants for cash TC BioPharm to slash 50% of workforce in cost saving effort Financial information for TC Biopharm","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4086237-tcbp-to-raise-treatment-capacity-with-expanded-manufacturing-process","is_publish_highlight":false,"gpt_icon":0},{"id":"2424846017","title":"TCBP Increasing Treatment Capacity with Expanded Manufacturing Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2424846017","media":"PR Newswire","top":-1,"share":"https://ttm.financial/m/news/2424846017?lang=en_us&edition=fundamental","pubTime":"2024-04-02 20:30","pubTimestamp":1712061000,"startTime":"0","endTime":"0","summary":"Developing streamlined approach to reduce cost per patient by 85%. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company's intent or ability to affect any budget savings or execute on any M&A or capital raising strategy. These statements are based on management's current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including that the proposed issuance of shares may not be approved by the Company's shareholders. For o","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/S1ywtgWkTyBMA9v2Wp1fGQ--~B/aD05OTt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/5faf2d4fcc480f0191397337ea4850ce","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/S1ywtgWkTyBMA9v2Wp1fGQ--~B/aD05OTt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/5faf2d4fcc480f0191397337ea4850ce"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/tcbp-increasing-treatment-capacity-expanded-123000947.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tcbp-increasing-treatment-capacity-expanded-123000947.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2420746298","title":"CGC, ATOS and MODG are among pre market gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2420746298","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2420746298?lang=en_us&edition=fundamental","pubTime":"2024-03-20 20:17","pubTimestamp":1710937077,"startTime":"0","endTime":"0","summary":"Gainers: Treasure Global  +47%. Taysha Gene Therapies  +28% Q4 earnings call release  Nature's Miracle Holding  +23%. PDD Holdings  +16% soars over 10% on Q4 beat as transaction services revenue .  Getty Images Holdings  +14%. MicroCloud Hologram  +14%.  Canopy Growth  +13%. SCWorx  +13%. Acelyrin  +11% Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease.  Topgolf Callaway Brands  +10%. Lufax Holding  +10%. BitFuFu  +9%. Eyenovia  +9%. TC BioPharm  +7%. Kingsoft Cloud Holdings  +7%. Atossa Therapeutics  +6% climbs after cancer therapy update.  Jiuzi Holdings  +6%. ImmunoPrecise Antibodies  +6% acquires Carterra LSA instrument.    More on premarket gainers & stock  Topgolf Callaway Brands: Cheap Valuation Relative To Peers Post Earnings Topgolf Callaway Brands Corp.  Q4 2023 Earnings Call Transcript Topgolf Callaway Brands Corp. 2023 Q4 - Results - Earnings Call Presentation Topgolf C","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4081519-cgc-atos-and-modg-are-among-pre-market-gainers","is_publish_highlight":false,"gpt_icon":0},{"id":"2420477564","title":"Canopy Growth, Outlook Therapeutics, Immuneering among healthcare movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2420477564","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2420477564?lang=en_us&edition=fundamental","pubTime":"2024-03-18 22:00","pubTimestamp":1710770418,"startTime":"0","endTime":"0","summary":"Gainers: Exagen  +20%. Immuneering  +26%. Elicio Therapeutics  +19%. Leafly Holdings  +18%. Canopy Growth  +16%.  Losers: CareMax  -25%. Abeona Therapeutics  -16%. TC BioPharm plc ADR  -15%. Amylyx Pharmaceuticals  -8%. Outlook Therapeutics  -11%.  S&P 500 Health Care Sector +0.1% to 1692.1. Health Care Equipment & Services -0.05% to 1974.99. Pharmaceuticals, Biotechnology & Life Science which contributes 58% to index is +0.19% to 1380.08.  More on Health Care Select Sector SPDR  XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Johnson & Johnson, Boston Scientific least shorted stocks in S&P 500 healthcare sector for Feb-end Waters, Moderna most shorted stocks in S&P 500 health sector till Jan-end","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4080472-canopy-growth-outlook-therapeutics-immuneering-among-healthcare-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2420799514","title":"TCBP announces exercise of series D warrants for cash","url":"https://stock-news.laohu8.com/highlight/detail?id=2420799514","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2420799514?lang=en_us&edition=fundamental","pubTime":"2024-03-18 21:09","pubTimestamp":1710767347,"startTime":"0","endTime":"0","summary":"TC BioPharm  has announced that an institutional investor has exercised cash only warrants represented 623,750 ADS at an exercise price of $2.02. The gross proceeds of the warrant exercise was $1,263,000 with a net cash infusion of $1,168,275 to the Co. post fees associated with the exercise to HC Wainwright & Co.  The Company intends to use the cash for additional working capital. \"This cash infusion further strengthens our balance sheet and is an example of the institutional investor interest the Company is garnering around it's clinical programs and the therapeutic applications for TCB-008.\" said CEO Bryan Kobel.   More on TC Biopharm  TC BioPharm to slash 50% of workforce in cost saving effort Financial information for TC Biopharm","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4080436-tcbp-announces-exercise-of-series-d-warrants-for-cash","is_publish_highlight":false,"gpt_icon":0},{"id":"2420845476","title":"TCBP Announces Exercise of Series D Warrants For Cash","url":"https://stock-news.laohu8.com/highlight/detail?id=2420845476","media":"PR Newswire","top":-1,"share":"https://ttm.financial/m/news/2420845476?lang=en_us&edition=fundamental","pubTime":"2024-03-18 20:30","pubTimestamp":1710765000,"startTime":"0","endTime":"0","summary":"Company receives gross proceeds of $1.26 M from transaction. EDINBURGH, Scotland, March 18, 2024 /PRNewswire/ -- TC BioPharm  PLC  a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that an institutional investor has exercised cash only warrants represented 623,750 American Depository Shares  at an exercise price of $2.02.The gross proceeds of the warrant exercise was $1,263,000 with a net cash infusion of $1,168,275 to the Company post fees associated with the exercise to HC Wainwright & Co. There was no additional consideration or inducement paid for the exercise of the Series D warrants in this transaction. The Company intends to use the cash for additional working capital.\"This transaction is further reflective of the promise of TCB-008 and The Company as whole,\" stated CEO Bryan Kobel. \"We will continue to execute on our 2024 plan, driving to human data in AML as well as expanding our","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/S1ywtgWkTyBMA9v2Wp1fGQ--~B/aD05OTt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/5faf2d4fcc480f0191397337ea4850ce","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/S1ywtgWkTyBMA9v2Wp1fGQ--~B/aD05OTt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/5faf2d4fcc480f0191397337ea4850ce"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/tcbp-announces-exercise-series-d-123000237.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tcbp-announces-exercise-series-d-123000237.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2419655098","title":"FGEN, LEXX and SGLY among mid-day movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2419655098","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2419655098?lang=en_us&edition=fundamental","pubTime":"2024-03-13 00:21","pubTimestamp":1710260471,"startTime":"0","endTime":"0","summary":"Gainers: ClearOne  +114%. Regulus Therapeutics  +105%. Singularity Future Technology Ltd  +46%. Ranpak Holdings Corp  +41%. ATRenew  +21%. MicroCloud Hologram  +21%. Heritage Insurance Holdings  +19%. TC BioPharm  +19%. Forian  +19%. FibroGen  +17%.   Losers: Simpple Ltd.  -40%. Lexaria Bioscience Corp  -31%. Blade Air Mobility  -30%. Vincerx Pharma  -29%. Power & Digital Infrastructure Acquisition II Corp  -27%. Solidion Technology  -26%. Caribou Biosciences  -24%. Renalytix  -23%. Psyence Biomedical Ltd.  -21%. SolarMax Technology  -21%.   More on Mid-day movers & stocks.  FibroGen, Inc. 2023 Q4 - Results - Earnings Call Presentation FibroGen, Inc.  Q4 2023 Earnings Call Transcript Lexaria to test DehydraTECH GLP-1 product for weight loss, diabetes Lexaria slips despite FDA nod to test blood pressure drug Seeking Alpha’s Quant Rating on FibroGen","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4078523-fgen-lexx-and-sgly-among-mid-day-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2418363826","title":"Lexicon Pharmaceuticals, Mesoblast, Ventyx Biosciences among healthcare movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2418363826","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2418363826?lang=en_us&edition=fundamental","pubTime":"2024-03-11 22:00","pubTimestamp":1710165656,"startTime":"0","endTime":"0","summary":"Gainers: TC BioPharm  plc ADR  +129%. Trxade Health  +29%. Lexicon Pharmaceuticals  +21%. Mesoblast ADR  +15%. Marpai  +11%.  Losers: CERo Therapeutics  -22%. Ventyx Biosciences  -21%. Ainos  -20%. Psyence Biomedical  -12%.  Immuron Limited ADR  -8%.  S&P 500 Health Care Sector -0.14% to 1700.92. Health Care Equipment & Services -0.09% to 1977.76. Pharmaceuticals, Biotechnology & Life Science which contributes 58% to index is -0.16% to 1391.64.  More on Health Care Select Sector SPDR  XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted stocks in S&P 500 health sector till Jan-end UBS concedes it wasn't bullish enough on stocks","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4077994-lexicon-pharmaceuticals-mesoblast-ventyx-biosciences-among-healthcare-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2418685143","title":"US Stocks Down; Dow Falls 100 Points","url":"https://stock-news.laohu8.com/highlight/detail?id=2418685143","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2418685143?lang=en_us&edition=fundamental","pubTime":"2024-03-11 21:47","pubTimestamp":1710164876,"startTime":"0","endTime":"0","summary":"U.S. stocks traded lower this morning, with the Dow Jones index dipping around 100 points on Monday.\n\nFollowing the market opening Monday, the Dow traded down 0.27% to 38,618.51 while the NASDAQ fell 0.16% to 16,058.93. The S&amp;P 500 also fell, dropping, 0.24% to 5,111.38.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/03/37586889/us-stocks-down-dow-falls-100-points","is_publish_highlight":false,"gpt_icon":0},{"id":"2418635018","title":"ETRN, CRDF and KC are among pre market gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2418635018","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2418635018?lang=en_us&edition=fundamental","pubTime":"2024-03-11 21:30","pubTimestamp":1710163853,"startTime":"0","endTime":"0","summary":"Kidpik  +281%. L.S. Starrett  +59% Enters Into a Merger Agreement With MiddleGround Capital to Become Private Company.  TC BioPharm  +57%. Unusual Machines  +34%. Auddia  +27%. Sonnet BioTherapeutics  +20% Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy  Met the Study’s Initial Pre-Specified Objective.  Mesoblast  +19% Crypto-linked stocks, MESO and more  Graphite  +16%. 180 Life Sciences  +13%. NuScale Power Corporation  +15% to Participate in March and April 2024 Investor Conferences.  AirNet Technology  +15% Announces Changes in the Board of Directors  Mawson Infrastructure Group  +14%. GDS Holdings Limited  +14%. Amplify Energy  +13% oil sheen not related to its operations.  Kingsoft Cloud Holdings  +12%. Lexeo Therapeutics  +10% Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights.  Microstrategy  +10%. Marpai  +9%. Revelation Biosciences  +9%. Cardiff Oncology  +9%","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4077980-etrn-crdf-and-kc-are-among-pre-market-gainers","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tcbiopharm.com","stockEarnings":[{"period":"1week","weight":-0.1792},{"period":"1month","weight":-0.0274},{"period":"3month","weight":-0.3932},{"period":"6month","weight":-0.8082},{"period":"1year","weight":-0.9536},{"period":"ytd","weight":-0.5521}],"compareEarnings":[{"period":"1week","weight":-0.0357},{"period":"1month","weight":-0.0314},{"period":"3month","weight":0.0354},{"period":"6month","weight":0.186},{"period":"1year","weight":0.2062},{"period":"ytd","weight":0.0509}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.","exchange":"NASDAQ","name":"TC BioPharm","nameEN":"TC BioPharm"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"TC BioPharm(TCBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest TC BioPharm(TCBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"TC BioPharm,TCBP,TC BioPharm股票,TC BioPharm股票老虎,TC BioPharm股票老虎国际,TC BioPharm行情,TC BioPharm股票行情,TC BioPharm股价,TC BioPharm股市,TC BioPharm股票价格,TC BioPharm股票交易,TC BioPharm股票购买,TC BioPharm股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"TC BioPharm(TCBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest TC BioPharm(TCBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction